Search - tctmd.com

Displaying 261 - 280 of 555

Sort: Relevancy | Date

Presentation TCT 2016

Outcome Registries IV: The UK Absorb Registry

Presenter: Stephen G. Ellis, Corrado Tamburino, Andreas Baumbach

October 31, 2016

Presentation TCT 2016

Outcome Registries III: 2-Year Results From ASSURE

Presenter: Stephen G. Ellis, Corrado Tamburino, Detlef G. Mathey

October 31, 2016

Presentation TCT 2016

Outcome Registries II: Long-term Outcomes From ABSORB EXPAND and STEMI First

Presenter: Stephen G. Ellis, Corrado Tamburino, Robert-Jan van Geuns

October 31, 2016

Presentation TCT 2016

Outcome Registries I: Extended Results From ABSORB EXTEND

Presenter: Stephen G. Ellis, Corrado Tamburino, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

ABSORB China Clinical Outcomes at 2 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Runlin Gao

October 31, 2016

Presentation TCT 2016

ABSORB II Clinical Outcomes at 3 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Bernard R. Chevalier

October 31, 2016

Presentation TCT 2016

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Presenter: Stephen G. Ellis, Corrado Tamburino, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

Presenter: Elazer R. Edelman, Juan F. Granada, Richard J. Rapoza

October 31, 2016

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

Presenter: Antonio L. Bartorelli, Kenneth Chin, Ariel Furer

October 31, 2016

Presentation TCT 2016

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

Presenter: Michael J. Cowley, Franz-Josef Neumann, Joel Sainsous

October 31, 2016

Presentation TCT 2016

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

Presenter: Antonio L. Bartorelli, Kenneth Chin, Jens Wiebe

October 31, 2016

Presentation TCT 2016

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

Presenter: Antonio L. Bartorelli, Kenneth Chin, Rony Lahoud

October 31, 2016

Presentation TCT 2016

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Presenter: Jacques J. Koolen, Yoshinobu Onuma, Michael Haude

October 31, 2016

Presentation TCT 2016

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

Presenter: Jorge Gaspar, Davide Capodanno

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Advertisement

Outcome Registries IV: The UK Absorb Registry

Outcome Registries III: 2-Year Results From ASSURE

Outcome Registries II: Long-term Outcomes From ABSORB EXPAND and STEMI First

Outcome Registries I: Extended Results From ABSORB EXTEND

ABSORB China Clinical Outcomes at 2 Years

ABSORB II Clinical Outcomes at 3 Years

BVS at the Cusp of Complete Bioresorption: MLD and Vasomotion at 3-years in Absorb and Xience from the ABSORB II trial

Benchtop Testing of BRS Mechanical Properties (General and Absorb Specific): Expansion, Recoil, Side Branches, and More

ABSORB III Critique: Pros and Cons

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

TCT 60: Clinical Outcomes of Absorb Bioresorbable Vascular Scaffold (BVS) in Diabetic and Non-Diabetic Patients: Patient-Level Pooled Analysis From the ABSORB Randomized Trials

TCT 51: In-Hospital and One-Month Outcomes of 983 Patients Implanted With Bioresorbable Vascular Scaffolds for Acute Coronary Syndroms; Subgroup of the Prospective, All Comers, Controlled, Multicenter, FRANCE ABSORB Registry

TCT 58: Long-term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Scaffolds During Daily Practice Two-Year Results From the ISAR-ABSORB Registry

TCT 57: Impact of Lesion Length on One-Year Outcomes of Absorb Bioresorbable Vascular Scaffolds

TCT 30: Safety, Clinical Performance and Multi-Modality Imaging Data of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with De Novo Lesions in Native Coronary Arteries at 12-Month Follow-Up-BIOSOLVE-II

Rationale for and Design of ABSORB IV (Five-Year Results): What I Expect the Findings to Be But What Wont Surprise Me!

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content